ACHC to book $179M settlement in Q4; liquidity detailed

Rhea-AI Filing Summary

Acadia Healthcare (ACHC) agreed to settle a previously disclosed securities case for $179 million, with no admission or finding of liability and subject to preliminary and final approval by the District Court. The Company plans to fund the payment from approximately $30 million in anticipated insurance proceeds, plus cash on hand and existing credit lines.

Acadia will record the aggregate settlement amount, less associated tax benefits, as an expense for the quarter ending December 31, 2025. Because the settlement funds will be excluded from adjusted EBITDA, the Company stated this has no impact on previously announced financial guidance. As of September 30, 2025, cash and cash equivalents were $118.7 million, availability under the $1.0 billion revolving credit facility was $786.7 million, and the Consolidated Total Net Leverage Ratio was 3.4x.

Insights

Litigation & Accounting Analyst

$179M settlement expense booked in Q4; guidance unchanged.

Acadia Healthcare agreed to resolve a securities case for $179 million, with no admission of liability and court approvals required. Management plans to fund it using about $30 million in anticipated insurance proceeds, plus cash and existing credit lines, limiting immediate liquidity strain.

The Company will record the aggregate amount, net of tax benefits, as an expense in the quarter ending December 31, 2025. The payment is excluded from adjusted EBITDA, so previously announced guidance remains unchanged; GAAP earnings for Q4 will reflect the charge.

Liquidity was supported by $118.7 million in cash and $786.7 million of availability under a $1.0 billion revolver as of September 30, 2025. Actual cash outflow timing depends on court approvals; subsequent disclosures may detail settlement timing and any insurance recoveries.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/10/2025 - 04:30 PM Learn about SEC filing dates

FAQ

What did Acadia Healthcare (ACHC) announce in this 8-K?

Acadia agreed to settle a previously disclosed securities case for $179 million, with no admission of liability and subject to court approval.

How will ACHC fund the $179 million settlement?

The Company intends to use approximately $30 million in anticipated insurance proceeds, plus cash on hand and existing credit lines.

When will the settlement impact Acadia’s financials?

Acadia will record the aggregate settlement amount, less tax benefits, as an expense in the quarter ending December 31, 2025.

Does the settlement affect Acadia’s guidance or adjusted EBITDA?

The settlement funds will be excluded from adjusted EBITDA, so the Company stated it has no impact on previously announced guidance.

What liquidity did ACHC report as of September 30, 2025?

Cash and cash equivalents were $118.7 million, with $786.7 million available under a $1.0 billion revolving credit facility; leverage was 3.4x.

Is the settlement final?

No. It is subject to preliminary and final approval by the District Court following finalization of a stipulation of settlement.

false 0001520697 0001520697 2025-11-10 2025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 10, 2025

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-35331		45-2492228
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6100 Tower Circle, Suite 1000 Franklin, Tennessee		37067
(Address of Principal Executive Offices)		(Zip Code)

(615) 861-6000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ACHC		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 7, 2025, Acadia Healthcare Company, Inc. (“Acadia” or “the Company”) agreed to settle Acadia’s previously disclosed securities litigation in the United States District Court for the Middle District of Tennessee (the “District Court”), St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988 (the “Case”).

The settlement will fully resolve the Case and will include a release, with no admission or finding of liability by Acadia or any of its former or current officers. The settlement is subject to finalization in a stipulation of settlement and will be subject to preliminary and final approval by the District Court. Acadia agreed to pay an aggregate amount of $179 million as the monetary component of the settlement.

The Company currently intends to pay the funds associated with the settlement from a combination of approximately $30 million in anticipated insurance proceeds, cash on hand and existing credit lines. The Company will record the aggregate settlement amount, less associated tax benefits, as an expense for the quarter ending December 31, 2025.

Because the settlement funds will be excluded from adjusted EBITDA, the settlement has no impact on the Company’s previously announced financial guidance. The Company also affirmed that it maintains a strong financial position with sufficient capital to make strategic investments in its business. As of September 30, 2025, the Company had $118.7 million in cash and cash equivalents and $786.7 million available under its $1.0 billion revolving credit facility with a Consolidated Total Net Leverage Ratio of 3.4x.

The information furnished pursuant to Item 7.01 in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Cautionary Statements Regarding Forward-Looking Statements

The foregoing discussion of the Case and the settlement contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause the Company’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the Company undertakes no obligation to publicly update forward-looking statements. Investors should read the important risk factors described in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

(d)		Exhibits
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 10, 2025				ACADIA HEALTHCARE COMPANY, INC.
				By:		/s/ Brian P. Farley
						Brian P. Farley
						Executive Vice President, Secretary and General Counsel